• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report.

作者信息

Zirwas Matthew J, Wulff Katie, Beckman Kenneth

机构信息

Probity Medical Research, Columbus, Ohio.

Comprehensive Eye Care of Central Ohio, Westerville, Ohio.

出版信息

JAAD Case Rep. 2018 Dec 4;5(1):34-36. doi: 10.1016/j.jdcr.2018.10.016. eCollection 2019 Jan.

DOI:10.1016/j.jdcr.2018.10.016
PMID:30555883
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6280680/
Abstract
摘要

相似文献

1
Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report.lifitegrast联合治疗度普利尤单抗诱导的眼表疾病（DIOSD）：一例新病例报告。
JAAD Case Rep. 2018 Dec 4;5(1):34-36. doi: 10.1016/j.jdcr.2018.10.016. eCollection 2019 Jan.
2
Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report.两例度普利尤单抗相关的结膜炎伴眼表白细胞介素-8信使核糖核酸高表达：病例报告
Allergy Asthma Clin Immunol. 2022 Oct 2;18(1):89. doi: 10.1186/s13223-022-00727-6.
3
Prevalence and Characteristics of Dupilumab-Induced Ocular Surface Disease in Adults With Atopic Dermatitis.特应性皮炎成人患者度普利尤单抗治疗诱导的眼表疾病的发生率和特征。
Cornea. 2022 Oct 1;41(10):1242-1247. doi: 10.1097/ICO.0000000000002866. Epub 2021 Oct 19.
4
[Ocular symptoms associated with dupilumab in atopic dermatitis].[特应性皮炎中与度普利尤单抗相关的眼部症状]
Ned Tijdschr Geneeskd. 2019 Mar 21;163:D3227.
5
Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.特应性皮炎患者接受度普利尤单抗治疗相关结膜炎的风险因素。
JAMA Dermatol. 2018 Oct 1;154(10):1208-1211. doi: 10.1001/jamadermatol.2018.2690.
6
Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis.重度特应性皮炎患者接受度普利尤单抗治疗期间的眼部并发症。
Acta Derm Venereol. 2019 Apr 1;99(4):375-378. doi: 10.2340/00015555-3121.
7
Encounters and medication use for ocular surface disorders among patients treated with dupilumab: A cohort study.使用度普利尤单抗治疗的患者眼部表面疾病的就诊及用药情况：一项队列研究。
JAAD Int. 2021 Apr 29;4:1-9. doi: 10.1016/j.jdin.2021.03.009. eCollection 2021 Sep.
8
Dupilumab side effect in a patient with atopic dermatitis: a case report study.度普利尤单抗在一名特应性皮炎患者中的副作用：一项病例报告研究。
Biologics. 2019 May 13;13:79-82. doi: 10.2147/BTT.S195512. eCollection 2019.
9
Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin.治疗与度普利尤单抗相关的难治性结膜炎，在眼睑皮肤上应用局部吡美莫司。
Dermatol Ther. 2019 Nov;32(6):e13134. doi: 10.1111/dth.13134. Epub 2019 Nov 5.
10
Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion.特应性皮炎患者在接受和未接受度普利尤单抗治疗时的结膜炎情况——国际特应性皮炎理事会的调查和意见。
J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1224-1231. doi: 10.1111/jdv.15608. Epub 2019 May 6.

引用本文的文献

1
Conjunctivitis in Adults with Atopic Dermatitis Treated with Dupilumab: An Observational Study of Clinical Characteristics, Symptomatology, and Treatment.度普利尤单抗治疗成人特应性皮炎合并结膜炎：一项关于临床特征、症状学及治疗的观察性研究
Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03209-4.
2
Ocular Side Effects of Dupilumab: A Comprehensive Overview of the Literature.度普利尤单抗的眼部副作用：文献综述
J Clin Med. 2025 Apr 5;14(7):2487. doi: 10.3390/jcm14072487.
3
Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series.描述度普利尤单抗相关眼表疾病的慢性特征：一项回顾性病例系列分析。
BMJ Open Ophthalmol. 2022 May;7(1). doi: 10.1136/bmjophth-2021-000947.
4
Clinical Characteristics and Treatment for Dupilumab-Related Ocular Complications in Atopic Dermatitis Patients.特应性皮炎患者中与度普利尤单抗相关的眼部并发症的临床特征及治疗
Clin Ophthalmol. 2022 Mar 29;16:947-958. doi: 10.2147/OPTH.S336978. eCollection 2022.
5
Ocular Adverse Effects in Atopic Dermatitis Patients Treated With Dupilumab: A Bibliometric Analysis.使用度普利尤单抗治疗的特应性皮炎患者的眼部不良反应：一项文献计量分析
Front Med (Lausanne). 2022 Mar 3;9:802036. doi: 10.3389/fmed.2022.802036. eCollection 2022.
6
Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase.基于世界卫生组织的 VigiBase，与度普利尤单抗相关的眼部表面疾病。
Sci Rep. 2021 Jul 12;11(1):14293. doi: 10.1038/s41598-021-93750-3.
7
Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae.度普利尤单抗相关的眼表疾病：临床表现、治疗和长期后遗症。
Eye (Lond). 2021 Dec;35(12):3277-3284. doi: 10.1038/s41433-020-01379-9. Epub 2021 Jan 28.
8
Nonsteroid management of residual ocular surface disease on dupilumab (ROSDD).度普利尤单抗治疗后残留眼表疾病的非甾体类药物管理（ROSDD）
Int J Womens Dermatol. 2019 Aug 24;5(5):383. doi: 10.1016/j.ijwd.2019.08.007. eCollection 2019 Dec.
9
Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD)研究过敏性接触性皮炎在度普利尤单抗治疗后残留眼表疾病（ROSDD）中的作用
Int J Womens Dermatol. 2019 Nov 7;5(5):308-313. doi: 10.1016/j.ijwd.2019.10.001. eCollection 2019 Dec.
10
A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.《临床医师识别与处理度普利尤单抗相关性结膜炎指南》。
Drugs R D. 2019 Dec;19(4):311-318. doi: 10.1007/s40268-019-00288-x.

本文引用的文献

1
Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment.使用度普利尤单抗治疗的特应性皮炎患者发生的结膜炎——临床特征与治疗
J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1778-1780.e1. doi: 10.1016/j.jaip.2018.01.034. Epub 2018 Feb 9.
2
Cicatricial ectropion in a patient treated with dupilumab.使用度普利尤单抗治疗的患者出现瘢痕性睑外翻。
Am J Ophthalmol Case Rep. 2017 Jun 22;7:120-122. doi: 10.1016/j.ajoc.2017.06.017. eCollection 2017 Sep.
3
Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.功能失调性泪液综合征：干眼疾病及相关泪膜紊乱——诊断与治疗的新策略
Curr Opin Ophthalmol. 2017 Jan;27 Suppl 1(Suppl 1):3-47. doi: 10.1097/01.icu.0000512373.81749.b7.
4
Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.5.0% 立他司特滴眼液在干眼症患者中的安全性：一项为期1年的多中心随机安慰剂对照研究。
Cornea. 2016 Jun;35(6):741-8. doi: 10.1097/ICO.0000000000000803.
5
Rethinking dry eye disease: a perspective on clinical implications.重新审视干眼病：对临床意义的一种观点
Ocul Surf. 2014 Apr;12(2 Suppl):S1-31. doi: 10.1016/j.jtos.2014.02.002. Epub 2014 Feb 13.
6
Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.利福平眼科溶液 5.0%治疗干眼症：OPUS-1 期 3 研究结果。
Ophthalmology. 2014 Feb;121(2):475-83. doi: 10.1016/j.ophtha.2013.09.015. Epub 2013 Nov 26.
7
Tear film osmolarity: determination of a referent for dry eye diagnosis.泪膜渗透压：干眼诊断参考值的确定
Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4309-15. doi: 10.1167/iovs.05-1504.